Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Purchased by Telemus Capital LLC

Telemus Capital LLC increased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 5.0% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 19,921 shares of the medical research company’s stock after purchasing an additional 942 shares during the quarter. Thermo Fisher Scientific accounts for about 0.9% of Telemus Capital LLC’s investment portfolio, making the stock its 27th largest holding. Telemus Capital LLC’s holdings in Thermo Fisher Scientific were worth $10,574,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of TMO. Raleigh Capital Management Inc. increased its position in Thermo Fisher Scientific by 49.1% during the 3rd quarter. Raleigh Capital Management Inc. now owns 82 shares of the medical research company’s stock worth $41,000 after purchasing an additional 27 shares in the last quarter. Cedar Mountain Advisors LLC grew its position in Thermo Fisher Scientific by 107.0% in the fourth quarter. Cedar Mountain Advisors LLC now owns 89 shares of the medical research company’s stock valued at $47,000 after acquiring an additional 46 shares in the last quarter. Operose Advisors LLC grew its position in Thermo Fisher Scientific by 250.0% in the third quarter. Operose Advisors LLC now owns 105 shares of the medical research company’s stock valued at $53,000 after acquiring an additional 75 shares in the last quarter. Financial Connections Group Inc. acquired a new stake in Thermo Fisher Scientific in the fourth quarter valued at approximately $53,000. Finally, Valley National Advisers Inc. grew its position in Thermo Fisher Scientific by 40.5% in the third quarter. Valley National Advisers Inc. now owns 111 shares of the medical research company’s stock valued at $56,000 after acquiring an additional 32 shares in the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on TMO shares. The Goldman Sachs Group increased their price objective on shares of Thermo Fisher Scientific from $550.00 to $640.00 and gave the company a “buy” rating in a research report on Wednesday, April 10th. Sanford C. Bernstein reissued a “market perform” rating on shares of Thermo Fisher Scientific in a research report on Monday, January 8th. Citigroup began coverage on shares of Thermo Fisher Scientific in a research report on Monday, March 18th. They set a “neutral” rating and a $620.00 price target for the company. Evercore ISI raised their price target on shares of Thermo Fisher Scientific from $575.00 to $610.00 and gave the stock an “outperform” rating in a research report on Thursday, April 4th. Finally, Barclays downgraded shares of Thermo Fisher Scientific from an “overweight” rating to an “equal weight” rating and raised their price target for the stock from $475.00 to $555.00 in a research report on Wednesday, January 24th. Five investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $604.69.

Thermo Fisher Scientific Trading Up 0.7 %

Shares of NYSE TMO opened at $548.37 on Tuesday. Thermo Fisher Scientific Inc. has a one year low of $415.60 and a one year high of $603.82. The firm has a market capitalization of $209.32 billion, a PE ratio of 35.49, a PEG ratio of 2.30 and a beta of 0.80. The company has a current ratio of 1.75, a quick ratio of 1.39 and a debt-to-equity ratio of 0.67. The business has a 50-day moving average price of $571.30 and a two-hundred day moving average price of $528.18.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, January 31st. The medical research company reported $5.67 EPS for the quarter, topping analysts’ consensus estimates of $5.64 by $0.03. The firm had revenue of $10.89 billion during the quarter, compared to analyst estimates of $10.73 billion. Thermo Fisher Scientific had a return on equity of 18.78% and a net margin of 13.99%. The business’s quarterly revenue was down 4.9% compared to the same quarter last year. During the same period last year, the company posted $5.40 EPS. As a group, analysts predict that Thermo Fisher Scientific Inc. will post 21.51 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, April 15th. Stockholders of record on Friday, March 15th were issued a dividend of $0.39 per share. This represents a $1.56 annualized dividend and a dividend yield of 0.28%. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. The ex-dividend date was Thursday, March 14th. Thermo Fisher Scientific’s payout ratio is currently 10.10%.

Insider Activity

In related news, Director Debora L. Spar sold 164 shares of the business’s stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $546.97, for a total value of $89,703.08. Following the completion of the sale, the director now directly owns 1,207 shares in the company, valued at approximately $660,192.79. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, Director Debora L. Spar sold 164 shares of the business’s stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $546.97, for a total value of $89,703.08. Following the completion of the sale, the director now directly owns 1,207 shares in the company, valued at approximately $660,192.79. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $555.63, for a total value of $5,556,300.00. Following the completion of the transaction, the chief executive officer now directly owns 49,155 shares in the company, valued at $27,311,992.65. The disclosure for this sale can be found here. Insiders sold a total of 50,277 shares of company stock worth $28,513,384 in the last three months. 0.32% of the stock is owned by insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.